v3.22.2.2
Shareholders' Equity
 9 Months Ended
Sep. 30, 2022
Equity [Abstract]  
Shareholders' Equity Shareholders' Equity
Net Loss per Common Share
Diluted net loss per common share is the same as basic net loss per common share for all periods presented because the effects of potentially dilutive items were anti-dilutive given the Company’s net loss. The following common share equivalent securities have been excluded from the calculation of weighted-average common shares outstanding because the effect is anti-dilutive:
Anti-dilutive common share equivalentsSeptember 30, 2022September 30, 2021
Stock options1,885 2,824 
Restricted stock units4,726 7,669 
Warrants13,242 13,242 
Total anti-dilutive common share equivalents19,853 23,735 
Three Months Ended September 30,Nine Months Ended September 30,
2022202120222021
Numerator:
Net loss$(23,984)$(17,268)$(83,324)$(77,799)
Denominator:
Weighted-average common shares outstanding, basic and diluted106,453 100,437 103,643 93,823 
Net loss per common share, basic and diluted$(0.23)$(0.17)$(0.80)$(0.83)

At the Market Offering
On August 3, 2022, the Company filed a shelf registration statement on Form S-3 (the “Registration Statement”). Pursuant to the Registration Statement, the Company may offer and sell securities having an aggregate public offering price of up to $300,000. In connection with the filing of the Registration Statement, the Company also entered into a sales agreement (the “ATM Agreement”) with Cowen and Company, LLC (“Cowen”). Pursuant to the ATM Agreement, the Company may offer and sell, from time to time through Cowen, shares of common stock, having an aggregate offering price up to $100,000 under an at-the-market offering program (the “ATM”), which is included in the $300,000 of securities that may be offered pursuant to the Registration Statement. Pursuant to the ATM Agreement, the Company will pay Cowen a commission rate equal to 3.0% of the gross proceeds from the sale of any shares of common stock and reimburse certain legal fees. The ATM Agreement will terminate upon the earlier of (i) issuance and sale of all the shares as allowed within and (ii) termination of the ATM Agreement as permitted therein. During the three and nine months ended September 30, 2022, the Company has sold 542 shares of its common stock pursuant to the ATM Agreement for gross proceeds of $1,454 and net proceeds of $1,410. As a result equity issuance costs of $63 were netted with gross proceeds in equity during the three and nine months ended September 30, 2022. As of September 30, 2022, there was $98,546 remaining under the ATM.
Common Stock Purchase Agreement
On December 15, 2021, the Company entered into a common stock purchase agreement (the “Purchase Agreement”) with B. Riley Principal Capital, LLC (“B. Riley Principal Capital”). Pursuant to the Purchase Agreement, the Company has the right to sell to B. Riley Principal Capital up to the lesser of (i) $100,000 of newly issued shares of the Company’s common stock and (ii) the Exchange Cap, which is 20,143 shares of the Company’s common stock (subject to certain limitations and conditions), from time to time during the 24-month term of the Purchase Agreement. Sales of common stock pursuant to the Purchase Agreement, and the timing of any sales, are solely at the option of the Company, and the Company is under no obligation to sell any securities to B. Riley Principal Capital under the Purchase Agreement.
During the three and nine months ended September 30, 2022, the Company has sold an aggregate 360 and 3,510 shares of its Common Stock pursuant to the Purchase Agreement for aggregate proceeds, net of fees incurred of $56 and $456, of $1,298
and $10,117. As a result, deferred equity issuance costs of $0 and $587 were netted into equity during the three and nine months ended September 30, 2022. As of September 30, 2022, there were 16,436 shares reserved for the Purchase Agreement.